Additional Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Medical University of South Carolina - PPDS ( Site 4004)
    Charleston SC. 29425
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Stanford Health Care ( Site 4009)
    Palo Alto CA. 94304
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Cedars Sinai Medical Center ( Site 4010)
    Los Angeles CA. 90048
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Boston University School of Medicine ( Site 4021)
    Boston MA. 02118
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    University Of Alberta Hospital ( Site 4702)
    Edmonton AB. T6G 1W9
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    UCLA School of Medicine ( Site 4006)
    Los Angeles CA. 90095-1670
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Yale University ( Site 4017)
    New Haven CT. 06519
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Mayo Clinic - Scottsdale ( Site 4014)
    Phoenix AZ. 85054
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Mount Sinai Hospital [Toronto, Canada] ( Site 4700)
    Toronto ON. M5T 3L9
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Hospital For Special Surgery ( Site 4020)
    New York NY. 10021
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Cleveland Clinic Foundation ( Site 4019)
    Cleveland OH. 44195
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018)
    Baltimore MD. 21224
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Froedtert and Medical College of Wisconsin ( Site 4012)
    Milwaukee WI. 53226
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Pacific Arthritis Care Center ( Site 4008)
    Los Angeles CA. 90045
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    University of Pittsburgh Medical Center ( Site 4016)
    Pittsburgh PA. 15213
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Massachusetts General Hospital ( Site 4003)
    Boston MA. 02114
    View Details

  • Xenon MRI and Progressive ILD

    Duke University
    Durham NC. 27710
    View Details

  • BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease

    Weill Cornell Medical Center
    New York NY. 10065
    View Details

  • Genentech Validation Tool for Pulmonary Fibrosis

    Columbia University Irving Medical Center
    New York NY. 10032
    View Details

  • Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research

    Baylor Scott & White Research Institute
    Dallas TX. 75246
    View Details